logo
episode-header-image
Sep 2022
30m 12s

Episode 028: Lung Cancer Series, Pt. 6: ...

Rouleaux University Medical Center
About this episode

Lung cancer is one of the most commonly diagnosed type of cancer and so it is fitting that we start the first of our disease-specific oncology series with this diagnosis. An important component of treatment in lung cancer (and many other cancers) is the use of radiation. This week, we continue our discussion about the fundamentals of Radiation Oncology with our guest, Dr. Evan Osmundson. 

*We hear the terms “hypo-fractioned” and “hyper-fractionated” radiation. What do those mean?

- Fractionation, that is breaking up the total dose of radiation into smaller ones, has allowed patients to tolerate the radiation better. The repeat exposure allows the healthy tissue to repair, whereas the tumor is not able to heal as well

- Standard fractionation involves keeping the maximum dose per session at 1.8-2Gy/fraction. 

- Hyper-fractionation is when a patient gets multiple doses per day, each less than 2Gy. This is important in small cell lung cancer, where the standard dose of radiation is 1.5Gy twice daily

- Hypo-fractionation os when larger doses are given in each session, typically larger than 2.5-3Gy, often 4-5Gy per fraction. This is analogous to SBRT. 

*With regards to SBRT, how do you determine the number of sessions? 

- Typically 3-5 sessions, and this is based on data run through their computer algorithm that allows the dose to be tumoricidal.

- More sessions (more likely 5 sessions) if central tumor (<2cm central proximal bronchial tree) or ultra-central tumor (directly abutting bronchial tree/major vessel) or abutting the chest well. Poor outcomes in some studies with fewer sessions; 5 sessions seem to work well in central tumors, based on recent data.

- Logistically speaking, five sessions is also typically the maximum that insurance will pay for. 

*What’s the max size of the tumor that is amenable to SBRT?

- Most clinical trials have limited size to 5cm or less, but he has done SBRT to larger tumors. This is a case-by-case basis.

* How do you calculate the duration of treatment when we are going to do concurrent chemo-radiation?

- Treatment is usually 5 days a week, with the weekends off for patients

- In NSCLC, total 60Gy appears to be the standard of care, based on RTOG 0617 study. (J Clin Oncol 2020 Mar 1;38(7):706-714. doi: 10.1200/JCO.19.01162. Epub 2019 Dec 16.); practically this means about 6 weeks of treatment.

- In SCLC, Target 45Gy broken up into 1.5Gy TWICE daily OR 66Gy broken up into 2Gy ONCE daily is the standard of care based on CONVERT trial (Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.)

* What is your guidance to avoid brain toxicity, for instance with using SRS to the brain for a brain met? 

- There is a risk of brain necrosis from the synergism between certain chemotherapies/targeted agents that penetrate the blood-brain barrier with SRS that can cause radiation necrosis to the brain. This is particularly an issue with TKIs, such as osimertinib. Dr. Osmundson recommends holding TKIs about 5-7 days, if possible.

*What is proton therapy and how does it differ than “traditional” radiation therapy?

- With x-rays/photon therapy, the beam is attenuated and there is an exit dose that can affect the neighboring tissues. 

- With proton beams, there is a “Bragg-Peak” effect, whereby you can specify how deep you want to radiation to deposit with little exit dose. 

- Per Dr. Osmundson, we are not currently in a position to recommend proton therapy AT THIS TIME, but this may be changing. Research is being done to better be able to maneuver the beam angles. 

- Proton therapy is also very expensive at this time

A special thank you to our guest, Evan Osmundson, MD, PhD, Associate Professor in the Department of Radiation Oncology and serves as the Medical Director of Radiation Oncology at Vanderbilt University Medical Center in Nashville, TN!

Please visit our website (TheFellowOnCall.com) for more information

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Google Podcast

Up next
Sep 17
Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may al ... Show More
36m 11s
Sep 10
Episode 138: Follicular Lymphoma Series, Pt 3 - Relapsed/Refractory Management (non-cellular therapy options)
This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 ... Show More
29m 51s
Jun 2025
Episode 137: Follicular Lymphoma Series, Pt 2. - Front-line Management
This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do. Episode contents:- What is the front-line approach to management for locali ... Show More
30m 11s
Recommended Episodes
Apr 2025
#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Sanjay Mehta is a radiation oncologist with over 25 years of experience, and is currently the president of Century Cancer Centers in Houston, Texas ... Show More
2h 12m
Jan 2024
A Radiation Oncology Perspective on the PROSPECT Trial
Salma Jabbour, MD, Professor and Vice Chair of Radiation Oncology at Rutgers Cancer Institute, provides an invaluable perspective rooted in her extensive experience and passion for radiation oncology. Dr. Jabbour delves into the transformative changes witnessed in radiation oncol ... Show More
47m 13s
Sep 24
Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain
In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington U ... Show More
53m 8s
Dec 2024
2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Dr. Jacob Sands
For a probing discussion detailing the American Lung Association’s recent 2024 “State of Lung Cancer” report, we are joined by esteemed thoracic medical oncologist Dr. Jacob Sands of Dana-Farber Cancer Institute and Harvard Medical School. Offering insight into actionable targete ... Show More
33m 9s
Sep 2024
Beyond the Digest: September 2024
Beyond the Digest are bonus episodes to the DermSurgery Digest that include reviews of interesting and relevant articles in dermatologic surgery literature. This episode features articles from the Journal of the National Comprehensive Cancer Network(JNCCN), the Journal of the Ame ... Show More
32m 45s
Jun 2023
Novel Therapies in GI Oncology at ASCO23
Drs. Shaalan Beg and Shiraj Sen discuss notable advances in GI cancers featured at the 2023 ASCO Annual Meeting, including the PROSPECT and PRODIGE-23 trials in rectal adenocarcinoma, the MORPHEUS study in uHCC, and the NORPACT-1 trial in pancreatic head cancer. TRANSCRIPT     Dr ... Show More
18m 30s
Aug 2024
The Risks and Benefits of Taking a Break From Cancer Treatment
Dr. Shaalan Beg and Dr. Arjun Gupta discuss the rationale behind treatment breaks and assess the pros and cons based on feedback and data from patients with advanced-stage gastrointestinal cancers. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm ... Show More
18m 47s
Nov 2024
Cancer Cells Gone Wild: Real Biology Exposed
In this episode, Dr. Jessica Steier and Dr. Sarah Scheinman discuss the complexities of cancer with Dr. Joe Zundell, a cancer biologist. They explore the definition of cancer, its prevalence, and the hallmarks that characterize cancer cells. The conversation delves into the mecha ... Show More
59m 38s
Dec 2024
141. Back to Basics - The role of endocrine therapy in Breast Cancer
Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as delay disease progression. This episode dives into a past of phenomenal improvem ... Show More
24m 4s
Jul 31
Cure Pain and Improve Wound Healing using Light! Introducing Photobiomodulation in Dentistry – PDP234
Have you heard of Photobiomodulation (PBM)? Or are you thinking... ‘photo-what?!’ Is red light therapy just voodoo science—or is it already part of mainstream healthcare? Can PBM really help with wound healing, pain relief, and even reduce the risk of dementia? In this episode, P ... Show More
1h 4m